Alector Reports $22.9 Million Net Loss in Q1 2026, Improved from $40.5 Million Loss in Q1 2025

Alector, Inc. reported a net loss of $22.9 million for the first quarter of 2026, a significant improvement compared to a net loss of $40.5 million during the same period in 2025. The company's collaboration revenue decreased to $1.0 million from $3.7 million year-over-year, primarily due to reduced manufacturing-related activities associated with the nivisnebart Phase 2 study in Alzheimer’s disease. Total operating expenses also fell to $25.965 million from $48.369 million, driven by a reduction in research and development costs, which dropped from $33.6 million to $17.9 million, and general and administrative expenses, which decreased from $14.7 million to $8.1 million.

In terms of financial position, Alector's total assets decreased to $239.9 million as of March 31, 2026, down from $293.2 million at the end of 2025. The decline in assets was largely attributed to a reduction in marketable securities, which fell from $190.2 million to $129.6 million. The company’s cash and cash equivalents increased to $76.96 million from $65.8 million, reflecting a net increase in cash flow from investing activities, primarily due to the maturity of marketable securities. Alector's accumulated deficit reached $995 million, indicating ongoing challenges in achieving profitability.

Strategically, Alector has been focusing on its collaboration with GlaxoSmithKline (GSK) for the development of progranulin-elevating monoclonal antibodies. The company is responsible for funding up to $140.5 million in development costs for the Phase 2 trial of nivisnebart, which was recently discontinued due to a futility analysis. The company has also undergone significant workforce reductions, impacting approximately 47% of its staff in late 2025, as part of efforts to align resources with strategic priorities. As of May 1, 2026, Alector had 111,025,187 shares of common stock outstanding.

Looking ahead, Alector anticipates that its existing cash, cash equivalents, and marketable securities will provide sufficient runway to fund operations through at least 2027. However, the company acknowledges the need for additional capital to support ongoing research and development activities, particularly as it continues to advance its product candidates through preclinical and clinical stages. The company remains focused on its proprietary Alector Brain Carrier (ABC) platform, which aims to enhance the delivery of therapeutics across the blood-brain barrier, and is evaluating its pipeline for potential new candidates.